Rowland Carmichael Advisors’s Merck MRK Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q1
Sell
-2,446
Closed -$212K 344
2019
Q4
$212K Buy
+2,446
New +$201K 0.07% 276
2018
Q1
Sell
-15,525
Closed -$834K 323
2017
Q4
$834K Buy
15,525
+94
+0.6% +$5.21K 0.43% 72
2017
Q3
$943K Sell
15,431
-439
-3% -$26.6K 0.52% 55
2017
Q2
$971K Buy
15,870
+718
+5% +$43.7K 0.56% 46
2017
Q1
$919K Sell
15,152
-2,454
-14% -$149K 0.56% 46
2016
Q4
$989K Sell
17,606
-275
-2% -$16.1K 0.58% 49
2016
Q3
$1.06M Buy
17,881
+352
+2% +$20.6K 0.68% 46
2016
Q2
$964K Buy
17,529
+3,197
+22% +$170K 0.61% 53
2016
Q1
$724K Buy
+14,332
New +$702K 0.67% 47

Other funds holding MRK

Rowland Carmichael Advisors's MRK Position: Q1 2020 in Review

Rowland Carmichael Advisors sold out of Merck (MRK) in Q1 2020, closing a stake of 2,446 shares — an estimated $212K sold.

Rowland Carmichael Advisors first reported a position in MRK in Q1 2016 and held it in 9 quarters. The position peaked at $1.06M in Q3 2016. 2,477 funds tracked by Wall St. Rank hold MRK as of Q1 2020.

  • Rowland Carmichael Advisors reported no remaining Merck position as of Q1 2020 after selling out during the quarter.
  • Rowland Carmichael Advisors sold 2,446 Merck shares in Q1 2020, an estimated $212K.
  • Rowland Carmichael Advisors first reported a position in Merck in Q1 2016 and held it in 9 quarters.
  • Rowland Carmichael Advisors's Merck position peaked at $1.06M in Q3 2016.
  • 2,477 funds tracked by Wall St. Rank held Merck as of Q1 2020.

Based on Rowland Carmichael Advisors's 13F filing for Q1 2020, filed 20 Apr 2020.